Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human CD58/LFA-3 Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 10068CD050
This item is not returnable.
View return policy
Description
The Recombinant Human CD58/LFA-3 Fc Chimera Protein is derived from HEK293. The Recombinant Human CD58/LFA-3 Fc Chimera Protein has been validated for the following applications: Bioactivity.Specifications
P19256 | |
965 | |
50 μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution. | |
<0.10 EU per 1 μg of the protein by the LAL method. | |
Unconjugated | |
Recombinant | |
Lyophilized from a 0.2 μm filtered solution in PBS. |
Bioactivity | |
48 kDa | |
Human embryonic kidney cell,HEK293-derived human CD58/LFA-3 protein, (N-terminus) Human CD58 (Phe29-Arg215) Accession &Num; P19256 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
RUO | |
CD58/LFA-3 | |
Human | |
Reconstitute at 400 μg/mL in PBS. | |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining. |
Provide Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction